Tesetaxel

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tesetaxel
Tesetaxel.png
Systematic (IUPAC) name
(2aS,2bR,3S,4S,6S,8aR,10S,11aS,11bR,13aR)-2a-(acetyloxy)-6-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoyl]oxy}-10-[(dimethylamino)methyl]-4-hydroxy-7,11b,14,14-tetramethyl-2a,2b,3,4,5,6,8a,11a,11b,12,13,13a-dodecahydro-2H-4,8-methano[1,3]dioxolo[3,4]cyclodeca[1,2-d][1]benzoxet-3-yl benzoate
Clinical data
Legal status Investigational
Identifiers
CAS number 333754-36-2 YesY
ATC code None
PubChem CID 6918574
UNII UG97LO5M8Y YesY
Chemical data
Formula C46H60FN3O13 
Mol. mass 881.98 g/mol
 N (what is this?)  (verify)

Tesetaxel (DJ-927) is a drug being investigated for chemotherapy of various types of cancer, including breast cancer,[1] gastric cancer,[2] and other solid tumours.[3]

References[edit]

  1. ^ ClinicalTrials.gov NCT01609127 Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
  2. ^ ClinicalTrials.gov NCT01348009 Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
  3. ^
    1. REDIRECT Template:Cite pmid